Profil
David Licata is the founder of TORL Biotherapeutics LLC.
He is currently the Chief Executive Officer at 1200 Pharma LLC.
Postes actifs de David Licata
| Sociétés | Poste | Début |
|---|---|---|
1200 Pharma LLC
 1200 Pharma LLC Pharmaceuticals: MajorHealth Technology 1200 Pharma LLC engages in the provision of pre-clinical drug discovery and clinical approval timelines. The company is headquartered in Pasadena, CA. | Directeur Général | 01/11/2017 |
TORL Biotherapeutics LLC
 TORL Biotherapeutics LLC BiotechnologyHealth Technology TORL Biotherapeutics LLC is a clinical-stage biopharmaceutical company based in Culver City, CA. TORL Biotherapeutics LLC is focused on developing new antibodies, including monoclonal antibodies (mAbs) and drug conjugates (ADCs), to transform the lives of patients with various types of cancer. TORL has a strategic partnership with the Slamon Research Lab and has exclusive rights to a program of biologics-based drugs for novel cancer targets. The company's lead program, TORL-1-23, is an ADC directed towards cldn6 for patients with multiple cancers. In addition to this, TORL has four other clinical-stage antibody programs and is building a pipeline of novel ADCs and mAbs for cancers with high unmet medical needs. The company was founded by David Licata, and the CEO is Mark J. Alles. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
1200 Pharma LLC
1200 Pharma LLC Pharmaceuticals: MajorHealth Technology 1200 Pharma LLC engages in the provision of pre-clinical drug discovery and clinical approval timelines. The company is headquartered in Pasadena, CA. | Health Technology |
TORL Biotherapeutics LLC
TORL Biotherapeutics LLC BiotechnologyHealth Technology TORL Biotherapeutics LLC is a clinical-stage biopharmaceutical company based in Culver City, CA. TORL Biotherapeutics LLC is focused on developing new antibodies, including monoclonal antibodies (mAbs) and drug conjugates (ADCs), to transform the lives of patients with various types of cancer. TORL has a strategic partnership with the Slamon Research Lab and has exclusive rights to a program of biologics-based drugs for novel cancer targets. The company's lead program, TORL-1-23, is an ADC directed towards cldn6 for patients with multiple cancers. In addition to this, TORL has four other clinical-stage antibody programs and is building a pipeline of novel ADCs and mAbs for cancers with high unmet medical needs. The company was founded by David Licata, and the CEO is Mark J. Alles. | Health Technology |
